MDXG
MiMedx Group, Inc.
MDXG has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over MDXG overall, supported by stronger fundamentals and stronger modeled upside.
MDXG Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Stable | |
| Strong |
MDXG's balance sheet is currently strong, and its cash flow is stable, but its revenue and profitability are weak.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
MDXG PE Valuation
MDXG has no meaningful PE right now: it lost money over the past year.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR's PE is 13x, but its earnings don't support one, so it isn't a reliable read right now.
MDXG Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Decline | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect MDXG's earnings to grow and its profitability to improve, but its revenue to decline.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over MDXG on the outlook, with more favorable revenue expectations.
MDXG Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $0.07 | — |
| Q3 2026 | -$0.13 | -148% |
| Q2 2026 | $0.04 | -81% |
| Q1 2026 | $0.20 | -26% |
| Q4 2025 | $0.32 | +14% |
| Q3 2025 | $0.27 | -55% |
| Q2 2025 | $0.21 | -66% |
| Q1 2025 | $0.27 | -45% |
| Q4 2024 | $0.28 | -24% |
MDXG has swung to a loss: it lost $0.13 per share over the past year, after a profit the year before.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has the edge over MDXG on earnings quality, reporting a profit while its opponent remains loss making.
MDXG Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $62.3M | -45% |
| Q2 2026 | $64.4M | -35% |
| Q1 2026 | $59M | -33% |
| Q4 2025 | $118.1M | +27% |
| Q3 2025 | $113.7M | +35% |
| Q2 2025 | $98.6M | +13% |
| Q1 2025 | $88.2M | +4.1% |
| Q4 2024 | $92.9M | +7% |
MDXG's revenue is shrinking: $62M last quarter, down 45% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -19% | -38 points |
| Q2 2026 | -29% | -41 points |
| Q1 2026 | -27% | -37 points |
| Q4 2025 | 18% | +6 points |
| Q3 2025 | 20% | +6.2 points |
| Q2 2025 | 13% | -14 points |
| Q1 2025 | 9.3% | -6.2 points |
| Q4 2024 | 12% | -19 points |
MDXG's operating margin was −19% last quarter, down 38 points from the same quarter a year ago.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over MDXG on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR has the edge over MDXG on profitability, with a higher operating margin.
MDXG Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $3.9M | -87% |
| Q2 2026 | -$10M | -169% |
| Q1 2026 | $1.9M | -65% |
| Q4 2025 | $25M | +33% |
| Q3 2025 | $29.3M | +49% |
| Q2 2025 | $14.4M | -34% |
| Q1 2025 | $5.3M | -11% |
| Q4 2024 | $18.8M | +91% |
MDXG generated $21M in free cash flow over the past year, down 69% from the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over MDXG on cash flow, with more consistent year-over-year improvement.
MDXG Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -1.3% | -1.9M shares |
| 1 year | -2.6% | -3.8M shares |
| 3 years | +22% | +26.5M shares |
| 5 years | +32% | +35.1M shares |
| Available history | +36% | +38.9M shares |
MDXG has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $304,000 |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
MDXG Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | -10.1x | Net Cash |
| Q1 2026 | -3.4x | Net Cash |
| Q4 2025 | -2.2x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -2.2x | Net Cash |
| Q1 2025 | -1.5x | Net Cash |
| Q4 2024 | -1.4x | Net Cash |
| Q3 2024 | -0.9x | Net Cash |
MDXG has the edge over OSCR on leverage, with a lower net debt burden relative to earnings.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
MDXG Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 28.1 | Oversold |
| Stochastic | 15.2 | Oversold |
MDXG's weekly RSI is 28 (oversold) and its Stochastic is 15 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
MDXG PE vs Healthcare Sector
| Metric | MDXG | Sector median | Relative |
|---|---|---|---|
| PE | 98x | 26x | 278% above |
| PE % | 92 | 29 | 63 pts above |
MDXG has no meaningful PE right now: it lost money over the past year.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR has the edge over MDXG on valuation relative to its sector.
MDXG Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.09 | 21% below |
| 20 week MA | $4.24 | 24% below |
| 50 week MA | $4.52 | 28% below |
| 100 week MA | $5.92 | 45% below |
| 200 week MA | $6.31 | 49% below |
MDXG is in a downtrend: it's below all five of its weekly moving averages, and 49% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over MDXG on trend strength, trading above more of its moving averages.
MDXG Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $7.25 | $9.40 | +30% |
| 2021 | $9.40 | $6.49 | -31% |
| 2022 | $6.49 | $2.77 | -57% |
| 2023 | $2.77 | $8.77 | +217% |
| 2024 | $8.77 | $9.42 | +7.4% |
| 2025 | $9.42 | $6.90 | -27% |
| 2026 YTD | $6.90 | $3.24 | -53% |
MDXG's yearly returns have swung widely, from +217% in 2023 to −57% in 2022. It's down 53% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over MDXG on returns for 2026, with the stronger performance.